Transition from Insulin Degludec (Tresiba) to Insulin Glargine U-300 (Toujeo)
Transition from once-daily insulin degludec to once-daily insulin glargine U-300 can be performed by starting Toujeo at the same unit dose as the discontinued once-daily long-acting basal insulin. [1] Dose titration should be performed based on blood glucose monitoring results, with adjustments no more frequently than every 3 to 4 days. [1] Closer glucose monitoring is recommended during the initial weeks after the regimen change because the full glucose-lowering effect may not be apparent for at least 5 days. [1]
Initial Dose Selection
- For patients currently on once-daily long-acting insulin, Toujeo should be started at the same unit dose as the once-daily long-acting insulin dose that is being discontinued (unit-to-unit). [1]
Administration During the Switch
- Toujeo should be administered subcutaneously once daily at the same time each day. [1]
- Toujeo should not be diluted or mixed with other insulin products or solutions. [1]
Titration Frequency and Steady-State Considerations
- Toujeo dose should be titrated no more frequently than every 3 to 4 days. [1]
- The full glucose-lowering effect of Toujeo may not be apparent for at least 5 days after initiation. [1]
- During the regimen change, blood glucose monitoring frequency should be increased. [1]
Dose Adjustment Strategy Based on Glucose Monitoring
- Toujeo dosage should be individualized and titrated based on metabolic needs, blood glucose monitoring results, and glycemic control goal. [1]
- Co-administered glucose-lowering therapies should be adjusted per standard of care during initiation to minimize risk of hyperglycemia or hypoglycemia. [1]
Expected Need for Early Adjustment
- Patients switching from other basal insulins may experience higher average fasting plasma glucose levels in the first weeks of therapy, and higher Toujeo doses may be required to achieve similar glycemic control compared with some other basal insulins. [1]
Monitoring and Safety Checks During Transition
- Glucose monitoring should be performed daily during initiation to minimize risk of hyperglycemia. [1]
- Hypoglycemia risk should be considered during dose adjustments and should inform the timing and magnitude of titration. [1]
Clinical Follow-Up Schedule
- After the switch, reassessment for titration should occur on a 3- to 4-day cycle rather than daily dose changes. [1]
- Further titration should continue only after at least several days have elapsed to allow time for the full glucose-lowering effect to manifest. [1]
Reference Targets for Fasting Glucose Used in Basal Titration
Basal insulin titration targets should follow local protocol or the diabetes guideline fasting plasma glucose goal, with titration continued until the fasting goal is achieved without clinically significant hypoglycemia. [2]
Common Pitfalls to Avoid During Conversion
- Frequent dose changes that exceed the label-recommended titration interval should be avoided. [1]
- Under-monitoring during the early transition period should be avoided. [1]
- Mixing or diluting Toujeo should be avoided. [1]